Hidrocortisona Roussel (Hydrocortisone)

Hidrocortisona Roussel is prescribed for several endocrine and inflammatory conditions where glucocorticoid activity is required.

• Primary adrenal insufficiency (Addison’s disease) requiring cortisol replacement.
• Congenital adrenal hyperplasia with cortisol deficiency.
• Acute exacerbations of rheumatoid arthritis or systemic lupus erythematosus.
• Severe allergic reactions or asthma attacks unresponsive to inhaled therapy.
• Dermatologic autoimmune disorders such as pemphigus vulgaris when systemic therapy is indicated.
• Management of adrenal crisis as an emergency glucocorticoid replacement.

• Hydrocortisone acts as an agonist at intracellular glucocorticoid receptors. After oral absorption, the drug diffuses into cells and binds the receptor complex, translocating to the nucleus where it modulates gene transcription. This up‑regulates anti‑inflammatory proteins (e.g., annexin‑1) and down‑regulates pro‑inflammatory cytokines such as interleukin‑1, interleukin‑6, and tumor necrosis factor‑α, thereby reducing inflammation and suppressing immune responses. It also replaces endogenous cortisol in deficient states.

Oral hydrocortisone may be associated with a range of adverse reactions, from mild, frequently observed effects to rare but potentially life‑threatening events, and the likelihood varies with dose and duration.

Common

• Increased appetite or mild weight gain, often accompanied by a tendency to retain water.
• Fluid retention causing peripheral edema, which may be more noticeable in the lower extremities.
• Mood alterations such as irritability, anxiety, or transient euphoria, especially during dose adjustments.

Serious

• Severe infection due to immunosuppression, requiring prompt medical evaluation if fever or unexplained symptoms develop.
• Osteoporosis or increased fracture risk with prolonged therapy, particularly in older adults or those with pre‑existing bone loss.
• Adrenal insufficiency leading to crisis if the drug is stopped abruptly, characterized by hypotension, weakness, and possible shock.

When prescribing Hidrocortisona Roussel, clinicians should evaluate several safety considerations to minimize risk and ensure appropriate use.

• Assess baseline blood glucose and monitor for hyperglycemia, especially in diabetic patients.
• Evaluate bone mineral density before long‑term therapy and consider calcium/vitamin D supplementation.
• Screen for active infections; avoid initiating therapy in uncontrolled bacterial, viral, or fungal infections.
• Use the lowest effective dose for the shortest duration required to control the condition.
• Counsel patients on the need for gradual tapering to prevent adrenal withdrawal.
• Review concomitant medications that may increase the risk of electrolyte imbalance or hypertension.

Hydrocortisone can alter the pharmacokinetics or pharmacodynamics of several agents; awareness of these interactions helps optimize therapy and avoid reduced efficacy or increased toxicity.

Avoid

• Strong CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce hydrocortisone plasma concentrations.
• Concurrent use of systemic antifungal azoles (e.g., ketoconazole) can increase glucocorticoid levels and risk toxicity.
• High‑dose oral contraceptives may increase corticosteroid‑binding globulin, potentially lowering free hydrocortisone levels.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal bleeding.
• Anticoagulants such as warfarin, where glucocorticoids can affect INR stability.
• Diabetic medications, because hydrocortisone may raise blood glucose and require dose adjustments.